WANY
AUPH icon

Wealthspire Advisors (New York)’s Aurinia Pharmaceuticals AUPH Stock Holding History

Wealthspire Advisors (New York)’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,000
Closed -$11.1K – 1175
2025
Q3 		$11.1K Buy
+1,000
New +$10.9K ﹤0.01% 1970

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wealthspire Advisors (New York)'s AUPH Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2025, closing a stake of 1,000 shares — an estimated $11.1K sold.

Wealthspire Advisors (New York) first reported a position in AUPH in Q3 2025 and held it in 1 quarter. The position peaked at $11.1K in Q3 2025. 255 funds tracked by Wall St. Rank hold AUPH as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Aurinia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 1,000 Aurinia Pharmaceuticals shares in Q4 2025, an estimated $11.1K.
  • Wealthspire Advisors (New York) first reported a position in Aurinia Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Aurinia Pharmaceuticals position peaked at $11.1K in Q3 2025.
  • 255 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.